search
Back to results

Model Driven Diabetes Care (MDDC)

Primary Purpose

Diabetes Mellitus, Type 1

Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Few Touch Application
Diastat
Sponsored by
University Hospital of North Norway
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Diabetes Mellitus, Type 1

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Confirmed diagnosis with Diabetes Mellitus type 1 for at least one year.
  • Age over 18 years
  • Has basic familiarity with mobile phones, and uses mobile phone on a daily basis.

Exclusion Criteria:

  • Severe complications due to their diabetes.
  • Unable to understand or conform to the guidelines when presented with the phone's software.

Sites / Locations

  • University Hopital of North Norway

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Delayed Diastat

Diastat

Arm Description

Mobile phone application Few Touch Application (FTA) in the regular version, with Diastat turned on in week 12 post-enrollment.

Few Touch Application with Diastat module turned on in week 4 post-enrollment.

Outcomes

Primary Outcome Measures

Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12.
The number of self-measured blood glucose values < 4 mmol/L (72 mg/dL) or > 15 mmol/L (270 mg/dL) will be recorded during baseline (first 4 weeks post-enrollment/start of study) and during weeks 8-12 post-enrollment for all participants.

Secondary Outcome Measures

Change in HbA1c
HbA1c will be measured at the start of the study (week 1 post-enrollment) and during the last week of intervention (week 12 for the intervention group and week 20 for the active comparator group).

Full Information

First Posted
January 11, 2013
Last Updated
August 17, 2015
Sponsor
University Hospital of North Norway
Collaborators
University of Tromso, The Research Council of Norway
search

1. Study Identification

Unique Protocol Identification Number
NCT01774149
Brief Title
Model Driven Diabetes Care
Acronym
MDDC
Official Title
Data Driven Feedback as a Method to Improve Glycaemic Control in Type 1 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
March 2013 (undefined)
Primary Completion Date
August 2013 (Actual)
Study Completion Date
August 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital of North Norway
Collaborators
University of Tromso, The Research Council of Norway

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients with Diabetes Mellitus Type 1 using electronic self-help tools typically registers a large amount of data on their disease. The study intends to see if giving advanced feedback on these data can improve their blood glucose management.
Detailed Description
All patients will be given access to a mobile phone with the diabetes diary known as the Few Touch Application (FTA) installed. They may use either their own compatible Android handsets, or provided handsets. The study uses a delayed start design. Participants are randomized into two groups, who get access to the module "Diastat" after 4 and 12 weeks post-enrollment respectively. Each group uses the FTA with Diastat for 8 weeks post-intervention (i.e. access to Diastat). Diastat is a module within FTA that provides data-driven feedback to the patients using their own data. This module is based on the data recorded in a previous trial [1]. Three submodules are part of Diastat; Periodicity detection and visualization, multiscale trend detection based on the c-SiZer algorithm [2], and situation matching for insulin dosage [3]. Skrøvseth SO et al, Diabetes Technol Ther (2012) Skrøvseth SO et al, PLoS ONE (2012) Skrøvseth SO et al, Accepted for Advanced Technologies and Treatments for Diabetes, Paris, France, 2013.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 1

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Delayed Diastat
Arm Type
Active Comparator
Arm Description
Mobile phone application Few Touch Application (FTA) in the regular version, with Diastat turned on in week 12 post-enrollment.
Arm Title
Diastat
Arm Type
Experimental
Arm Description
Few Touch Application with Diastat module turned on in week 4 post-enrollment.
Intervention Type
Device
Intervention Name(s)
Few Touch Application
Other Intervention Name(s)
Diabetesdagboka
Intervention Description
Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.
Intervention Type
Device
Intervention Name(s)
Diastat
Intervention Description
Users get the Few Touch Application with Diastat module activated.
Primary Outcome Measure Information:
Title
Change in the Frequency of Hyper- and Hypo-glycemic Events From Baseline to Week 8-12.
Description
The number of self-measured blood glucose values < 4 mmol/L (72 mg/dL) or > 15 mmol/L (270 mg/dL) will be recorded during baseline (first 4 weeks post-enrollment/start of study) and during weeks 8-12 post-enrollment for all participants.
Time Frame
Up to 12 weeks post-enrollment
Secondary Outcome Measure Information:
Title
Change in HbA1c
Description
HbA1c will be measured at the start of the study (week 1 post-enrollment) and during the last week of intervention (week 12 for the intervention group and week 20 for the active comparator group).
Time Frame
up to 20 weeks post-enrollment
Other Pre-specified Outcome Measures:
Title
Usability
Description
System Usability Scale (SUS) will be applied to assess usability of the approach and recorded during the last week of intervention (week 12 for the intervention group and week 20 for the active comparator group).
Time Frame
up to 20 weeks post-enrollment
Title
Empowerment
Description
Diabetes Empowerment Scale-Short Form (DES-SF) will be used to assess empowerment at the start of the study (week 1 post-enrollment) and during week 12 of intervention.
Time Frame
Up to 12 weeks post-enrollment.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Confirmed diagnosis with Diabetes Mellitus type 1 for at least one year. Age over 18 years Has basic familiarity with mobile phones, and uses mobile phone on a daily basis. Exclusion Criteria: Severe complications due to their diabetes. Unable to understand or conform to the guidelines when presented with the phone's software.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stein Olav Skrøvseth, PhD
Organizational Affiliation
University Hospital of North Norway
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hopital of North Norway
City
Tromsø
ZIP/Postal Code
9038
Country
Norway

12. IPD Sharing Statement

Citations:
PubMed Identifier
23035775
Citation
Skrovseth SO, Arsand E, Godtliebsen F, Hartvigsen G. Mobile phone-based pattern recognition and data analysis for patients with type 1 diabetes. Diabetes Technol Ther. 2012 Dec;14(12):1098-104. doi: 10.1089/dia.2012.0160. Epub 2012 Oct 4.
Results Reference
background
PubMed Identifier
22874353
Citation
Skrovseth SO, Arsand E, Godtliebsen F, Joakimsen RM. Model driven mobile care for patients with type 1 diabetes. Stud Health Technol Inform. 2012;180:1045-9.
Results Reference
background
PubMed Identifier
23063047
Citation
Arsand E, Froisland DH, Skrovseth SO, Chomutare T, Tatara N, Hartvigsen G, Tufano JT. Mobile health applications to assist patients with diabetes: lessons learned and design implications. J Diabetes Sci Technol. 2012 Sep 1;6(5):1197-206. doi: 10.1177/193229681200600525.
Results Reference
background
PubMed Identifier
23300626
Citation
Skrovseth SO, Bellika JG, Godtliebsen F. Causality in scale space as an approach to change detection. PLoS One. 2012;7(12):e52253. doi: 10.1371/journal.pone.0052253. Epub 2012 Dec 27.
Results Reference
background
PubMed Identifier
23672413
Citation
Skrovseth SO, Arsand E, Godtliebsen F, Joakimsen RM. Model-driven diabetes care: study protocol for a randomized controlled trial. Trials. 2013 May 14;14:139. doi: 10.1186/1745-6215-14-139.
Results Reference
background
PubMed Identifier
25751133
Citation
Skrovseth SO, Arsand E, Godtliebsen F, Joakimsen RM. Data-Driven Personalized Feedback to Patients with Type 1 Diabetes: A Randomized Trial. Diabetes Technol Ther. 2015 Jul;17(7):482-9. doi: 10.1089/dia.2014.0276. Epub 2015 Mar 9.
Results Reference
derived

Learn more about this trial

Model Driven Diabetes Care

We'll reach out to this number within 24 hrs